Implication of MTOR Signaling in NSCLC: Mechanisms and Therapeutic Perspectives

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2023 Aug 11

PMID 37566093

Authors

Antonios N Gargalionis

Kostas A Papavassiliou

Athanasios G Papavassiliou

Affiliations

Soon will be listed here.

Abstract

Mechanistic target of the rapamycin (mTOR) signaling pathway represents a central cellular kinase that controls cell survival and metabolism. Increased mTOR activation, along with upregulation of respective upstream and downstream signaling components, have been established as oncogenic features in cancer cells in various tumor types. Nevertheless, mTOR pathway therapeutic targeting has been proven to be quite challenging in various clinical settings. Non-small cell lung cancer (NSCLC) is a frequent type of solid tumor in both genders, where aberrant regulation of the mTOR pathway contributes to the development of oncogenesis, apoptosis resistance, angiogenesis, cancer progression, and metastasis. In this context, the outcome of mTOR pathway targeting in clinical trials still demonstrates unsatisfactory results. Herewith, we discuss recent findings regarding the mechanisms and therapeutic targeting of mTOR signaling networks in NSCLC, as well as future perspectives for the efficient application of treatments against mTOR and related protein molecules.

References

Heavey S, OByrne K, Gately K . Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC. Cancer Treat Rev. 2013; 40(3):445-56. DOI: 10.1016/j.ctrv.2013.08.006. View

Chetty C, Lakka S, Bhoopathi P, Rao J . MMP-2 alters VEGF expression via alphaVbeta3 integrin-mediated PI3K/AKT signaling in A549 lung cancer cells. Int J Cancer. 2009; 127(5):1081-95. PMC: 2891576. DOI: 10.1002/ijc.25134. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Gargalionis A, Papavassiliou K, Basdra E, Papavassiliou A . mTOR Signaling Components in Tumor Mechanobiology. Int J Mol Sci. 2022; 23(3). PMC: 8837098. DOI: 10.3390/ijms23031825. View

Le X, Puri S, Negrao M, Nilsson M, Robichaux J, Boyle T . Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in -Mutant NSCLC. Clin Cancer Res. 2018; 24(24):6195-6203. PMC: 6295279. DOI: 10.1158/1078-0432.CCR-18-1542. View

Lim W, Zhang W, Miller C, Watters J, Gao F, Viswanathan A . PTEN and phosphorylated AKT expression and prognosis in early- and late-stage non-small cell lung cancer. Oncol Rep. 2007; 17(4):853-7. View

Zhao H, Wang Y, Ren X . Nicotine promotes the development of non-small cell lung cancer through activating LINC00460 and PI3K/Akt signaling. Biosci Rep. 2019; 39(6). PMC: 6554215. DOI: 10.1042/BSR20182443. View

Stefani C, Miricescu D, Stanescu-Spinu I, Nica R, Greabu M, Ripszky Totan A . Growth Factors, PI3K/AKT/mTOR and MAPK Signaling Pathways in Colorectal Cancer Pathogenesis: Where Are We Now?. Int J Mol Sci. 2021; 22(19). PMC: 8508474. DOI: 10.3390/ijms221910260. View

Mafi S, Mansoori B, Taeb S, Sadeghi H, Abbasi R, Cho W . mTOR-Mediated Regulation of Immune Responses in Cancer and Tumor Microenvironment. Front Immunol. 2022; 12:774103. PMC: 8894239. DOI: 10.3389/fimmu.2021.774103. View

10.

Vestergaard H, Christensen M, Lassen U . A systematic review of targeted agents for non-small cell lung cancer. Acta Oncol. 2017; 57(2):176-186. DOI: 10.1080/0284186X.2017.1404634. View

11.

Zha J, Xia Y, Ye C, Hu Z, Zhang Q, Xiao H . The Anti-Non-Small Cell Lung Cancer Cell Activity by a mTOR Kinase Inhibitor PQR620. Front Oncol. 2021; 11:669518. PMC: 8222575. DOI: 10.3389/fonc.2021.669518. View

12.

Shih M, Chen J, Wu Y, Jan Y, Yang B, Lu P . TOPK/PBK promotes cell migration via modulation of the PI3K/PTEN/AKT pathway and is associated with poor prognosis in lung cancer. Oncogene. 2011; 31(19):2389-400. DOI: 10.1038/onc.2011.419. View

13.

Zheng Z, Li Y, Lu X, Zhang J, Liu Q, Zhou D . A novel mTOR-associated gene signature for predicting prognosis and evaluating tumor immune microenvironment in lung adenocarcinoma. Comput Biol Med. 2022; 145:105394. DOI: 10.1016/j.compbiomed.2022.105394. View

14.

Lastwika K, Wilson 3rd W, Li Q, Norris J, Xu H, Ghazarian S . Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer. Cancer Res. 2015; 76(2):227-38. DOI: 10.1158/0008-5472.CAN-14-3362. View

15.

Papadimitrakopoulou V, Adjei A . The Akt/mTOR and mitogen-activated protein kinase pathways in lung cancer therapy. J Thorac Oncol. 2007; 1(7):749-51. View

16.

Colardo M, Segatto M, Di Bartolomeo S . Targeting RTK-PI3K-mTOR Axis in Gliomas: An Update. Int J Mol Sci. 2021; 22(9). PMC: 8124221. DOI: 10.3390/ijms22094899. View

17.

Liu H, Yin J, Wang C, Gu Y, Deng M, He Z . FOXO3a mediates the cytotoxic effects of cisplatin in lung cancer cells. Anticancer Drugs. 2014; 25(8):898-907. DOI: 10.1097/CAD.0000000000000117. View

18.

Kim D, Sarbassov D, Ali S, Latek R, Guntur K, Erdjument-Bromage H . GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol Cell. 2003; 11(4):895-904. DOI: 10.1016/s1097-2765(03)00114-x. View

19.

Guertin D, Stevens D, Thoreen C, Burds A, Kalaany N, Moffat J . Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell. 2006; 11(6):859-71. DOI: 10.1016/j.devcel.2006.10.007. View

20.

Aisner D, Sholl L, Berry L, Rossi M, Chen H, Fujimoto J . The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2). Clin Cancer Res. 2017; 24(5):1038-1047. PMC: 7008001. DOI: 10.1158/1078-0432.CCR-17-2289. View